Prostate Cancer Clinical Trial
Replication of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Full Description
This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.
Eligibility Criteria
Please see https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV for full code and algorithm definitions.
Eligible cohort entry dates:
The degarelix indication for treatment of prostate cancer was approved by the FDA on Dec 24, 2008. Leuprolide was initially approved for the same indication prior to Dec 24, 2008.
IBM MarketScan: Dec 24, 2008 - December 31, 2018 (end of available data) Optum CDM: Dec 24, 2008 - June 30, 2020 (end of available data) CMS Diabetes: Dec 24, 2008 - Dec 31, 2017 (end of available data)
Inclusion Criteria:
Histologically confirmed adenocarcinoma of the prostate
Pre-existing ASCVD (confirmed diagnosis, documented) according to a least 1 of the following criteria:
Previous MI >= 30 days before randomization
Previous revascularization procedure >= 30 days before randomization
Coronary artery: stent placement/balloon angioplasty or coronary artery bypass graft surgery
Carotid artery: stent placement/balloon angioplasty or endarterectomy surgery
Iliac, femoral, popliteal arteries: stent placement/balloon angioplasty or vascular bypass surgery
Exclusion Criteria:
Treatment naivety (ADT)
Previous or current hormonal management of prostate cancer including surgical castration, any hormonal manipulation, or any previous neoadjuvant/adjuvant hormonal therapy, unless treatment was terminated more than 12 months prior to enrollment
Uncontrolled Type 1 or Type 2 diabetes mellitus
Uncontrolled hypertension
A history of congenital long QT syndrome or risk factors for Torsade de pointes ventricular arrhythmias
MI; stroke; or coronary, carotid, or peripheral artery revascularization
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Boston Massachusetts, 02120, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.